Richardpruen (talk | contribs) (Started page) |
Richardpruen (talk | contribs) (Edit for content) |
||
| Line 15: | Line 15: | ||
* Caponnetto P, Campagna D, Ahluwalia JS, Russell C, Maglia M, Riela PM, Longo CF, Busa B, Polosa R. Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial. BMC Med. 2023 Jul 5;21(1):220. doi: 10.1186/s12916-023-02919-2. | * Caponnetto P, Campagna D, Ahluwalia JS, Russell C, Maglia M, Riela PM, Longo CF, Busa B, Polosa R. Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial. BMC Med. 2023 Jul 5;21(1):220. doi: 10.1186/s12916-023-02919-2. | ||
* E-cigarette abstinence rate in the varenicline + counseling group was 34.3%, significantly higher than the abstinence rate of 17.2% in the placebo + counseling group. Notably, no subject in the study relapsed to tobacco cigarette smoking. | * E-cigarette abstinence rate in the varenicline + counseling group was 34.3%, significantly higher than the abstinence rate of 17.2% in the placebo + counseling group. Notably, no subject in the study relapsed to tobacco cigarette smoking. | ||
* '''Note:''' Varenicline has risks, it should be discussed with a doctor aware of vaping, if the risks outweigh the benefits of stopping vaping (as they may in many vapers), then it would not be warranted. | |||
{{Stub}} | |||
[[Category:Studies, Surveys, and Papers]] | |||
edits